344 related articles for article (PubMed ID: 23037768)
1. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
[TBL] [Abstract][Full Text] [Related]
4. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
5. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Seko Y; Akuta N; Suzuki F; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
Intervirology; 2013; 56(1):13-21. PubMed ID: 22907167
[TBL] [Abstract][Full Text] [Related]
6. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
Khokhar N; Niazi TK; Qureshi MO
J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
[TBL] [Abstract][Full Text] [Related]
8. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
[TBL] [Abstract][Full Text] [Related]
9. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
Main J
J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
[TBL] [Abstract][Full Text] [Related]
10. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
13. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.
Chemello L; Cavalletto L; Bernardinello E; Guido M; Pontisso P; Alberti A
J Hepatol; 1995; 23 Suppl 2():8-12. PubMed ID: 8720287
[TBL] [Abstract][Full Text] [Related]
14. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
15. Current status of hepatitis C virus infection in Korea.
Suh DJ; Jeong SH
Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
[TBL] [Abstract][Full Text] [Related]
17. Therapy of hepatitis C: patients with cirrhosis.
Schalm SW; Fattovich G; Brouwer JT
Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
[TBL] [Abstract][Full Text] [Related]
18. Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model.
Ikeda K; Kawamura Y; Kobayashi M; Fukushima T; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2014; 86(5-6):295-302. PubMed ID: 24924385
[TBL] [Abstract][Full Text] [Related]
19. [Antiviral therapy of hepatitis C].
Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
